Decreased Serum Level of miR-146a as Sign of Chronic Inflammation in Type 2 Diabetic Patients by Lucy Baldeón R. (674016)

“…</p><p></p><p></p><p>The serum levels of miR-146a were significantly reduced in T2D patients as compared to these non-diabetic, but obese/dyslipidemic control group (mean patients 0.61, mean controls set at 1; p = 0.042), those of miR-155 were normal.…”

Apoptosis induction, ROS production and the decrease in MMP by DX1 treatment in HL-60 cells. by Zhiying Yu (356965)

<i>N</i>-acylethanolamine hydrolysis inhibitors decrease N1E-115 cell viability. by Laurie Hamtiaux (199349)

Methamphetamine exposure decreases midbrain neuronal activity via a D₂ receptor mechanism. by Douglas R. Miller (7406591)

Compared to vorinostat, M344 decreases pancreatic cancer cell proliferation more effectively for a longer duration. by Shelby M. Knoche (13833807)

Specific inhibition of ATG5 and ATG7 decrease low glucose-induced LC3-II accumulation. by Delphine Balmer (458897)

“…<b>B)</b> Quantification of <i>Atg5</i> mRNA expression was performed by PCR and results expressed as mean ± SEM of 2 experiments performed in duplicate, *p<0.002. …”

Absence of PICALM results in a decreased rate of internalization and increased cell surface expression of TfR in MEFs. by Paula B. Scotland (138601)

GHD in Nestin-Cre mice leads to a decrease in STAT5 phosphorylation, lower expression of <i>Igf1</i> and an increase in the expression of <i>CD36</i> and <i>Vldlr</i> in the liver. by Jeroen Declercq (783867)

PPP2R5C HepKD in <i>db/db</i> mouse liver improves insulin sensitivity, decreases hyperglycemia, but worsens the dyslipidemia. by Yong-Sheng Cheng (803758)

“…<p><b>(A)</b> Hyperglycemia in <i>db/db</i> mice is decreased upon hypatocyte-specific PPP2R5C knockdown with adeno-associated virus. …”

Decrease in <i>Sox2</i> expression results in similar phenotypes as disruptions to FGFR1 signaling. by Lu M. Yang (6919364)

Presentation_1_Eosinophils Decrease Pulmonary Metastatic Mammary Tumor Growth.pptx by Rachel A. Cederberg (12827564)

“…We found that IL5Tg mice exhibit reduced pulmonary metastatic colonization and decreased metastatic tumor burden compared to wild-type (WT) mice or eosinophil-deficient mice. …”

GREAT GO analysis of WDR5 and MYCN overlapped ChIP-seq peaks with >2.5-fold decrease of WDR5 signal intensity after the silencing of <i>WDR5</i>. by Zhihui Liu (95891)

LRP1 interacts with GluA1 and regulates its turnover in neurons. by Ming Gan (673850)

Subjects:

Ameliorative effect of yokukansan on glutamate-induced decrease in GSH levels in PC12 cells. by Hitomi Kanno (584976)

POS treatment decreases ROS level and upregulates mitochondrial biogenesis in ARPE-19 cells through PGC-1α. by Murilo F. Roggia (755997)

“…<p><b>(A)</b> POS treatment upregulated mRNA levels of anti-oxidant enzymes including GPx1, GPx4, SOD1 and catalase. …”

ATRA decreases mRNA expression of HO-1, GCLM and x-CT and lowers GSH level in BTZ-treated cells. by A. L. Furfaro (2587792)

Decrease of p38 MAPK phosphorylation in HL60 and KG1a cells exposed to 5-Fluorouridine (FUrd) after cell pretreatment with p38 MAPK pathway inhibitor SB202190. by Sabine Matou-Nasri (2938941)

“…<p>The KG1a and HL60 cells were pre-treated with 10 μM SB202190 for 2 h incubation then followed by the cell treatment with 10 μM of FUrd. …”

Inhibition of ATR activation significantly decreases B19V-induced G2 arrest in infected CD36⁺ EPCs. by Peng Xu (17962)

Structure of YOLOv5s-SBC. by Zhongjian Xie (4633099)

“…The experimental results showed that P-YOLOv5s-GRNF increased the mAP(mean average precision) by 0.8%, 4.3%, 3.2%, 0.7%, 19.3%, 9.8%, 3.1% compared to mainstream object detection algorithms YOLOv5s, YOLOv6s, YOLOv7-tiny, YOLOv8s, YOLOv5s-Shufflenetv2, YOLOv5s-Mobilenetv3, YOLOv5s-Ghost, respectively. …”

ATRA decreases the binding of Nrf2 to ARE sequences in the promoter regions of HO-1, GCLM and x-CT in BTZ-treated cells. by A. L. Furfaro (2587792)